On October 10, 2024, Boxer Capital, LLC significantly increased its investment in Tyra Biosciences Inc., acquiring an additional 85,939 shares. This transaction raised the firm's total holdings in the company to 6,534,298 shares.
Boxer Capital, LLC is recognized for its strategic investments in innovative biotechnology entities. The increased stake reflects a substantial commitment to Tyra Biosciences as a key component of its investment strategy.
This move by a prominent institutional investor signals a strong belief in Tyra Biosciences' precision medicine platform and its pipeline of Fibroblast Growth Factor Receptor (FGFR) inhibitors, which are aimed at addressing unmet needs in oncology and skeletal conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.